Serious and invasive pediatric pneumococcal disease: Epidemiology and vaccine impact in the USA

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Serious and invasive infections caused by Streptococcus pneumoniae continue to be a major cause of morbidity and mortality worldwide. The introduction of a hepatavalent pneumococcal conjugate vaccine (PCV7) in 2000 in the USA has had a significant impact on decreasing the incidence of serious and invasive pneumococcal disease in all age groups, especially in children under 2 years of age. However, the emergence of replacement nonvaccine pneumococcal serotypes (e.g., 19A, 3, 15 and 33) has resulted in an increase in the incidence of serious and invasive infections. The scope of disease caused by these emerging serotypes is not fully known, and the development of other pneumococcal conjugate vaccines is critical in order to control the amount of invasive disease that is currently being seen. The objective of this review is to discuss the current epidemiology of serious and invasive pneumococcal infections post-PCV7 introduction in the USA and review the pneumococcal vaccines that are in development.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalExpert Review of Anti-Infective Therapy
Volume8
Issue number2
DOIs
StatePublished - Feb 1 2010

Keywords

  • conjugate pneumococcal vaccine
  • invasive pneumococcal disease
  • pneumococcal bacteremia
  • pneumococcal meningitis
  • pneumococcal pneumonia

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Serious and invasive pediatric pneumococcal disease: Epidemiology and vaccine impact in the USA'. Together they form a unique fingerprint.

  • Cite this